NASDAQ$NTLA
Intellia Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported operational highlights and financial results.
Intellia Therapeutics reported progress in advancing its pipeline of CRISPR-based gene editing therapies, including the initiation of the HAELO Phase 3 study and continued strong enrollment in the MAGNITUDE Phase 3 study. The company ended the quarter with $944.7 million in cash, cash equivalents and marketable securities.
- Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-end
- Strong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans
- Actively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE)
- On track to dose the first patient by year-end in the Phase 1/2 study of NTLA-3001, an in vivo gene insertion candidate for the treatment of alpha-1 antitrypsin deficiency (AATD)
Headline financials
Revenue & EPS history
Intellia · Revenue · Quarterly
$9.11M
Forward guidance
Intellia expects to dose the first patient in the Phase 1/2 study of NTLA-3001 by year-end.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
20 / 40 earnings
Positive
+20.4%
Q4 2021
Best reaction
-21.0%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | -3.1% | -13.4% | |
| Q4 2025 | +6.2% | +1.4% | -7.8% | |
| Q3 2025 | -9.2% | -25.0% | -29.2% | |
| Q1 2025 | +13.6% | +14.1% | +11.0% | |
| Q4 2024 | +0.6% | -15.8% | -25.3% | |
| Q3 2024 | +4.2% | +3.7% | -8.3% | |
| Q2 2024 | +0.7% | +5.2% | -7.5% | |
| Q1 2024 | +6.3% | +11.9% | -1.2% | |
| Q4 2023 | -2.9% | +15.4% | +0.1% | |
| Q3 2023 | -15.2% | -7.0% | +2.0% | |
| Q2 2023 | -0.3% | +0.8% | -5.1% | |
| Q1 2023 | +13.8% | +14.0% | +6.2% | |
| Q4 2022 | -3.1% | +3.2% | -1.6% | |
| Q3 2022 | -0.3% | -3.1% | -9.7% | |
| Q2 2022 | -11.7% | -15.7% | -21.9% | |
| Q1 2022 | -14.6% | -20.3% | -18.7% | |
| Q4 2021 | +20.4% | -0.2% | -11.7% | |
| Q3 2021 | -0.3% | +1.8% | -25.7% | |
| Q2 2021 | +13.9% | +6.1% | +20.3% | |
| Q1 2021 | -5.1% | -7.3% | +1.2% | |
| Q4 2020 | -5.1% | -2.7% | +1.6% | |
| Q3 2020 | +3.3% | +8.6% | +59.9% | |
| Q2 2020 | +0.9% | -0.4% | -7.8% | |
| Q1 2020 | -1.5% | +14.7% | +46.9% | |
| Q4 2019 | +8.6% | +9.6% | -3.1% | |
| Q3 2019 | +15.5% | +8.7% | +47.2% | |
| Q2 2019 | -2.7% | -4.1% | -21.6% | |
| Q1 2019 | +9.5% | +11.7% | -4.0% | |
| Q4 2018 | +5.0% | +14.3% | +17.7% | |
| Q3 2018 | +4.0% | +3.1% | -3.3% | |
| Q2 2018 | -0.2% | +2.7% | +16.2% | |
| Q1 2018 | +6.4% | +4.7% | +35.4% | |
| Q4 2017 | -21.0% | -29.2% | -33.9% | |
| Q3 2017 | -10.9% | -23.2% | -21.2% | |
| Q2 2017 | -9.6% | -4.4% | +24.9% | |
| Q1 2017 | -9.0% | -10.7% | -20.2% | |
| Q4 2016 | -4.0% | +0.6% | -2.6% | |
| Q3 2016 | -5.7% | +1.1% | +12.7% | |
| Q2 2016 | +14.0% | +5.9% | +11.9% | |
| Q1 2016 | +3.1% | -0.1% | -26.0% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro